Evaluation the Sensitivity and Specificity of Fucose and Some Biochemical Parameters as an Indicator of Therapeutic Response to Metformin in Polycystic Ovary Syndrome
Biomarkers PCOS
DOI:
https://doi.org/10.32441/ijms.6.3.6Keywords:
PCOS, Fucose, galactose, MetforminAbstract
The present study aimed to evaluate the sensitivity and specificity of fucose and some biochemical parameters, as an indicator of therapeutic response to Metformin in patients with recently diagnosed with Polycystic Ovary Syndrome-PCOS undergoing treatment. This study was conducted from 1/9/2022 to 1/11/2022. In 90 blood samples were collected from women aged between (35-18) years old. Of these, 30 samples were taken from women who had recently been diagnosed with polycystic ovary syndrome as a first group-G1, and another 30 samples were taken from the same group of women after taking metformin medication as second group-G2, compared to 30 samples taken from healthy women with no history of the disease (as a control group-C). Samples were collected from women's clinics and external laboratories (after diagnosis from the doctor) in Samarra city/ Salah Ul-Din. The study includes determination of the concentration of sex hormones(Follicle stimulating hormone-FSH, luteinizing hormone-LH, and testosterone) and some biochemical parameters(Galactose, blood glucose, total fucose-TF, and fucose binding protein-FBP) in sera of samples under investigation. There was a significant increase in the levels of FSH and Glucose in a G1 at a probability level (P≤0.05). However, there was a significant decrease in total fucose and FBP, with no-significant difference in the levels of LH, testosterone, Galactose as compared with the control group. There was a significant increase in G2 at a probability level (P≤0.05) in the levels of Testosterone, Galactose, glucose with a significant decrease in the levels of TF and FBP, with no-significant difference in the level of LH, FSH and transaminases enzymes as compared with the control group. The study also include study the Receiver operating characteristic-ROC , In G1 as compared with C showed that the Sensitivity was also recorded as highest for galactose , In G2 as compared with C showed that the area under curve was outstanding for galactose, Sensitivity was also recorded as highest for galactose , In G1 as compared with G2 showed that the area under curve was outstanding for galactose. Sensitivity was also recorded as highest for galactose, then for Testosterone and total fucose. From the above results we can conclude that the level of fucose may be used as a diagnostic biomarker for polycystic ovary syndrome and also for treatment response with metformin. We conclude from the current study that the level of fucose may be considered a diagnostic indicator for polycystic ovarian cysts, as well as an indicator of the therapeutic response to uremia in patients.
References
Maqbool ZM, Irfat M. Polycystic ovary syndrome and infertility: an update. International Journal of Adolescent Medicine and Health.2022;34(2):1-9.
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Oxf Engl. 2016;31: 2841–2855.
Scheindlin S. Clinical enzymology: Enzymes as medicine. Molecular interventions.2007; 7(1): 4.
Noh HK, KimIH, LeeHJ, JooJK. PO-RE04: The relationship between ovarian volume and related clinical-hormonal parameters in Korean women with polycystic ovary syndrome . 2020; 106: 272-272.
Marbut MM, Awwad NY, Yousif MN, Ahmed MS. Hormonal assessment in women with polycystic ovary syndrome in Tikrit city. Journal of Madenat Alelem University College.2019; 11(1): 1-9.
Ehrmann DA. Polycystic ovary syndrome. New England Journal of Medicine. 2005; 352(12): 1223-1236.
Rocha AL, Oliveira FR, Azevedo RC, Silva VA, Peres TM, Candido AL, et al. Recent advances in the understanding and management of polycystic ovary syndrome. F1000Research. 2019;8. pmid:31069057.
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Yildiz BO. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction. 2018; 33(9): 1602–1618.
Deswal R, Nanda S, Dang AS. Association of Luteinizing hormone and LH receptor gene polymorphism with susceptibility of Polycystic ovary syndrome. Systems Biology in Reproductive Medicine. 2019; 65(5): 400-408.
Mehrabani S, Arab A, Karimi E, Nouri M, Mansourian M. Blood circulating levels of Adipokines in polycystic ovary syndrome patients: a systematic review and Meta-analysis. Reproductive Sciences.2021; 28(11): 3032-3050.
Dische Z, Shettles LB. A specific color reaction of methylpentoses and a spectrophotometric micromethod for their determination. Journal of Biological Chemistry. 1948;175(2): 595-603.
Shettles LB, Dische Z , Osnos M. Neutral mucopolysaccharide of the human cervical mucus. Journal of Biological Chemistry.1951; 192(2): 589-93.
Liu RB, Liu Y, Lv LQ, Xiao W, Gong C, Yue JX. Effects of metformin treatment on soluble leptin receptor levels in women with polycystic ovary syndrome. Current Medical Science. 2019; 39: 609-614.
Atoum MF, Alajlouni MM, Alzoughool FA. case-control study of the luteinizing hormone level in luteinizing hormone receptor gene (rs2293275) polymorphism in polycystic ovarian syndrome females. Public Health Genomics. 2022; 25(3-4): 89-97.
Abdelazim IA, Alanwar A, AbuFaza M, Amer OO, Bekmukhambetov Y, Zhurabekova G, Shikanova S, Karimova BE. levated and diagnostic androgens of polycystic ovary syndrome. Przeglad menopauzalny Menopause review. 2020; 19(1): 1–5 .
Elsirgany S, Badawi H, El-Khayat Z, Bibers M, Hamdy M, Hamdy A, Alalfy, M. Serum fetuin a level: a new possible marker for polycystic ovarian syndrome in women with infertility. Obstetrics and Gynecology Research. 2019; 2(4): 100-107.
Mahdi HA, Al-Samarrai RRH. Evaluation the correlation between the level of asprosin and some biochemical parameters in women with polycystic ovary syndrome. Samarra Journal of Pure and Applied Science.2021; 3(2): 12-24.
Brown JB. Pituitary control of ovarian function—concepts derived from gonadotrophin therapy. Australian and New Zealand Journal of Obstetrics and Gynaecology.1978; 18(1): 47-54.
Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecological endocrinology. 2003; 17(1): 51-6.
Suman Rice, Androulla Elia, Zara Jawad, Laura Pellatt, Helen D. Mason. Metformin Inhibits Follicle-Stimulating Hormone (FSH) Action in Human Granulosa Cells: Relevance to Polycystic Ovary Syndrome, The Journal of Clinical Endocrinology & Metabolism.2013; Volume 98: Issue 9, 1 September .Pages E1491–E1500.
Coutinho EA, Kauffman AS. The role of the brain in the pathogenesis and physiology of polycystic ovary syndrome (PCOS). Medical Sciences. 2019; 7(8): 84.
Esparza LA, Schafer D, Ho BS, Thackray VG, Kauffman AS. Hyperactive LH pulses and elevated kisspeptin and NKB gene expression in the arcuate nucleus of a PCOS mouse model. Endocrinology. 2020; 161(4): bqaa018.
Deswal R, Nanda S, Dang AS. Association of Luteinizing hormone and LH receptor gene polymorphism with susceptibility of Polycystic ovary syndrome. Systems Biology in Reproductive Medicine. 2019; 65(5): 400-408.
Alfatlawi WR. Study the effect of Interleukin36 gamma and AMH in Iraqi women with PCOS. Al-Mustansiriyah Journal of Science. 2017; 28(3): 151-156.
Baqer LS, Ahmeid MS, Al-Obaidi AH. Evaluation the effect of metformin on hormones serum levels in women with polycystic ovary syndrome. Tikrit Journal of Pure Science. 2018; 22(9): 1-5.
Fattah A, Al-Kader DA, Amaowei EEJ, Amini H, Hewadmal H, Rasuli SF, FarooqMJA. Comparative Study of Luteinizing Hormone Levels in Polycystic Ovarian Syndrome With Hyperandrogenism: Metformin Versus Oral Contraceptive Pills. Cureus. 2022; 14(9).
Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F , Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertility and sterility.2004; 81(1): 114-119.
Omear HA, fauzy Shehab A, Al-Assie AH. Plymorphism of CYP17 for Polycystic Ovarian Syndrome in Women of Salah Al-Din Provence/Iraq. Journal of Biotechnology Research Center. 2014; 8(1): 50-54.
Lerchbaum E, Schwetz V, Rabe T, Giuliani A, Obermayer-Pietsch B. Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype. PLoS One. 2014; 9(10): e108263.
AlFaisal AHM, Al-Deresawi MSG. The correlation between thyroid hormones, reproductive hormones, body mass index (BMI) and hirsute in Iraqi women with polycystic ovary syndrome (PCOS). J Univ Anbar Pure Sci. 2013; 7: 1-6.
Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy, AA. Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome. Saudi medical journal.2007; 28(7): 1039.
McCartney CR , Marshall JC. Polycystic ovary syndrome. New England Journal of Medicine. 2016; 375(1): 54-64.
Na Z, Jiang H, Meng Y, Song J, Feng D, Fang Y, Shi B, Li D. Association of galactose and insulin resistance in polycystic ovary syndrome: A case-control study. EClinicalMedicine. 2022; Apr 16;47:101379.
Daghestani MH, Daghestani M, Daghistani M.et al. A study of ghrelin and leptin levels and their relationship to metabolic profiles in obese and lean Saudi women with polycystic ovary syndrome (PCOS). Lipids in health and disease. 2018; 17(1): 1-9.
Hussainl ZM. A, Jafar AK, Al-Nakash ARH. Plasma Homocysteine and Insulin Resistance in Patients with Polycystic Ovary Syndrome. IRAQI POSTGRADUATE MEDICAL JOURNAL. 2022; 21(3): 326.
Ibraheem QA, Al Obaidy LHA, Nasir GA, Al-Obaidi MTM. Fat Mass and Obesity Association gene Polymorphism in PCOS Iraqi Women. Diabetes. 2020; 17(3): 1103-1112.
Lashen H. Role of metformin in the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2010; Jun;1(3):117-28.
Imbs TI, Skriptsova AV, Zvyagintseva TN. Antioxidant activity of fucose-containing sulfated polysaccharides obtained from Fucus evanescens by different extraction methods. Journal of Applied Phycology. 2015; 27(1):545-53.
Uçkan K, Demir H, Turan K, Sarıkaya E, Demir C. Role of oxidative stress in obese and nonobese PCOS patients. International Journal of Clinical Practice.2022.
Papalou OM, Victor V, Diamanti-Kandarakis E. Oxidative stress in polycystic ovary syndrome. Current pharmaceutical design.2016; 22(18): 2709-2722.
Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Human reproduction update.2013; 19(3): 268-288.
Hu S, Chen S, Zhu H, Du M, Jiang W, Liu Y, Xu Y. Low Molecular Weight, 4-O-Sulfation, and Sulfation at Meta-Fucose Positively Promote the Activities of Sea Cucumber Fucoidans on Improving Insulin Resistance in HFD-Fed Mice. Marine Drugs. 2022;20(1): 37.
Moloney DJ, Haltiwanger RS. The O-linked fucose glycosylation pathway: identification and characterization of a uridine diphosphoglucose: fucose-β1, 3-glucosyltransferase activity from Chinese hamster ovary cells. Glycobiology. 1999; 9(7):679-87.
Wiweko B, Maidarti M, Priangga MD. et al. Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients. J Assist Reprod Genet . 2014; 31: 1311–1316.
Obeid SF, Hassan BF , Alhaidari TK. Serum anti-Mullerian hormone level as a marker of polycystic ovarian syndrome in Iraqi women. Al-Kindy College Medical Journal. 2015; 11(1): 28-31.
